Audentes Therapeutics Inc (BOLD) PT Set at $24.00 by Piper Jaffray Cos.
Audentes Therapeutics Inc (NASDAQ:BOLD) has been given a $24.00 target price by research analysts at Piper Jaffray Cos. in a research report issued to clients and investors on Monday. The brokerage currently has a a “buy” rating on the stock. Piper Jaffray Cos.’s target price would suggest a potential upside of 30.86% from the company’s previous close.
Several other analysts also recently commented on the company. Wedbush reaffirmed an “outperform” rating and set a $20.00 price objective on shares of Audentes Therapeutics in a research note on Thursday, September 1st. Cowen and Company assumed coverage on Audentes Therapeutics in a research note on Monday, August 15th. They set an “outperform” rating on the stock.
Audentes Therapeutics (NASDAQ:BOLD) traded up 1.80% during mid-day trading on Monday, hitting $18.67. The stock had a trading volume of 13,767 shares. The company’s market capitalization is $405.61 million. The stock’s 50-day moving average is $15.80 and its 200 day moving average is $15.45. Audentes Therapeutics has a 52 week low of $13.06 and a 52 week high of $19.26.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/11/audentes-therapeutics-inc-bold-pt-set-at-24-00-by-piper-jaffray-cos.html
In other news, insider James E. Flynn purchased 400,000 shares of the company’s stock in a transaction on Monday, July 25th. The shares were purchased at an average price of $15.00 per share, with a total value of $6,000,000.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Orbimed Advisors Llc purchased 33,334 shares of the company’s stock in a transaction on Monday, July 25th. The stock was purchased at an average cost of $15.00 per share, for a total transaction of $500,010.00. The disclosure for this purchase can be found here.
Audentes Therapeutics Company Profile
Audentes Therapeutics, Inc is a biotechnology company. The Company focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. Its portfolio of product candidates include AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
Receive News & Ratings for Audentes Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.